RxDoctor Payments DataLook up a doctor →

Lawrence Zimnoch, MD

Internal Medicine · Washington, DCNPI 1881611556

Payments from drug & device makers

$21,886in general payments, 2019–2025

Across 1,132 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$4K
  • Viiv Healthcare Company$3K
  • AbbVie$2K
  • AstraZeneca$1K
  • Pfizer$1K
  • Novo Nordisk$955
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$120%
  • Food & beverage$21,71699%
  • Education$1581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead211$4,426
Viiv Healthcare Company152$3,434
AbbVie(2 entities)112$1,993
AstraZeneca59$1,168
Pfizer69$1,026
Novo Nordisk53$955
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC71$923
Otsuka America Pharmaceutical, Inc.36$706
Lilly USA, LLC34$689
Theratechnologies Inc.25$660
Johnson & Johnson(2 entities)33$647
Takeda Pharmaceuticals U.S.A., Inc.30$572
Merck31$557
Amgen22$463
Lundbeck LLC20$449
GSK9$215
Biohaven Pharmaceuticals, Inc.13$170
Boehringer Ingelheim7$151
Biohaven Pharmaceutical Holding Company Ltd.21$151
Astellas Pharma US Inc4$149
Amarin Pharma, Inc.8$137
Neos Therapeutics, LP11$133
Axsome Therapeutics, Inc.5$126
Exact Sciences4$105
Jazz Pharmaceuticals Inc.5$104
Idorsia Pharmaceuticals US Inc5$98
Dynavax Technologies Corporation7$90
Kowa Pharmaceuticals America, Inc.5$85
Bausch Health US, LLC3$75
Napo Pharmaceuticals Inc5$74
Harmony Biosciences LLC2$72
Abbott4$70
Mylan Institutional Inc.3$68
Sumitomo Pharma America, Inc.3$65
Sanofi Pasteur Inc.3$65
Janssen Products, LP2$60
Eisai Inc.3$58
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)2$57
Antares Pharma, Inc.2$52
Mylan Pharmaceuticals Inc.2$48
Acerus Pharmaceuticals Corporation3$47
Esperion Therapeutics, Inc.2$46
Dexcom, Inc.1$44
Teva Pharmaceuticals USA, Inc.2$41
Arbor Pharmaceuticals, Inc.3$40
Paratek Pharmaceuticals, Inc.2$38
Avadel CNS Pharmaceuticals, LLC1$37
Inspire Medical Systems, Inc.1$29
Aytu Biopharma, Inc.2$29
Quidel Corporation1$28
Tolmar, Inc.1$27
Incyte Corporation1$26
Neurocrine Biosciences, Inc.1$25
E.r. Squibb & Sons, L.L.C.1$23
Janssen Scientific Affairs, LLC1$23
Novartis1$23
Dermira, Inc.1$22
Vertical Pharmaceuticals, LLC1$22
Alkermes, Inc.1$22
Galderma Laboratories, L.p.1$21

How this compares

$21,886 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.

See all internal medicine providers in District of Columbia

Medicare billing

Part B allowed, 2024
$84,964
Medicare patients
219
Services billed
1,248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala21$90,749
DescovyEmtricitabine/Tenofov Alafenam19$77,559
JulucaDolutegravir/Rilpivirine12$49,059
MounjaroTirzepatide21$21,503
RybelsusSemaglutide12$11,309
EliquisApixaban17$10,736
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,939
LinzessLinaclotide13$7,796
Doxycycline Ir-DrDoxycycline Monohydrate11$4,463
NexlizetBempedoic Acid/Ezetimibe11$4,372
Testosterone15$2,427
Irbesartan65$2,141
SynthroidLevothyroxine Sodium32$2,054
Candesartan Cilexetil21$1,696
Valsartan25$1,505

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$4,426$168,30840 claims
Viiv Healthcare CompanyJuluca$3,434$49,05912 claims
Lilly USA, LLCMounjaro$689$21,50321 claims
Novo NordiskRybelsus$955$11,30912 claims
PfizerEliquis$1,026$10,73617 claims
AbbVieLinzess, Synthroid$1,993$9,85045 claims
GSKTrelegy Ellipta$215$7,93913 claims
Esperion Therapeutics, Inc.Nexlizet$46$4,37211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.

Other internal medicine in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →